Page last updated: 2024-12-08

6-o-monoacetylmorphine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

6-O-monoacetylmorphine: RN given refers to parent cpd(5alpha,6alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5462507
CHEMBL ID592009
CHEBI ID2168
SCHEMBL ID7940016
MeSH IDM0088072

Synonyms (33)

Synonym
morphine 6-acetate
morphine 6-acetate (6ci,7ci)
6-o-acetylmorphine
morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-, 6-acetate
ymorphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, 6-acetate (9ci)
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-, 6-acetate
6-mam
monoacetylmorphine
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, 6-acetate, (5alpha,6alpha)-
morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, 6-acetate (8ci)
o6-monoacetylmorphine
o(sup 6)-monoacetylmorphine
o6-acetylmorphine
7,8-didehydro-4,5alpha-epoxy-17-methylmorphinan-3,6alpha-diol 6-acetate
6-o-monoacetylmorphine
6-acetylmorphine
2784-73-8
chebi:2168 ,
CHEMBL592009
unii-m5e47p1zch
m5e47p1zch ,
6-acetyl morphine
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5.alpha.,6.alpha.)-, 6-acetate
SCHEMBL7940016
DTXSID60182154
heroin-m 6-mam
6-acetylmorphine 0.1 mg/ml in acetonitrile
6-acetylmorphine 1.0 mg/ml in acetonitrile
bdbm224020
6-monoaceylmorphine
Q2406967
[(4r,4ar,7s,7ar,12bs)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate
PD017203

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" These pharmacodynamic studies, along with prior dispositional studies, suggest that the ability of DAM and AM to rapidly cross the blood-brain barrier determines their potency and time-action differences from M in centrally mediated bioassays."( Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetylmorphine and morphine in mice.
Inturrisi, CE; Umans, JG, 1981
)
0.26
" Nevertheless, the terminal half-life of 60-90 min resembles that of morphine and is maintained by the rate-determining return of distributed heroin from esterase-free tissues."( Pharmacokinetics of morphine and its surrogates IV: Pharmacokinetics of heroin and its derived metabolites in dogs.
Garrett, ER; Gürkan, T, 1980
)
0.26
"To develop an integrated population pharmacokinetic model for heroin (diamorphine) and its pharmacodynamically active metabolites 6-acetylmorphine, morphine, morphine-3-glucuronide and morphine-6-glucuronide."( Population pharmacokinetics of heroin and its major metabolites.
Beijnen, JH; Huitema, AD; Rook, EJ; van den Brink, W; van Ree, JM, 2006
)
0.33
" Here, we use pharmacokinetic modeling on data from the aforementioned study to calculate parameters of the distribution of heroin, 6-MAM and morphine in blood and brain tissue after subcutaneous heroin administration in mice."( Pharmacokinetic modeling of subcutaneous heroin and its metabolites in blood and brain of mice.
Andersen, JM; Boix, F; Mørland, J, 2013
)
0.39
" In order to optimize conditions for measuring heroin and its metabolites in samples collected for pharmacokinetic studies in rats, we investigated the time course of degradation of heroin, 6-MAM, and morphine in four biological matrices: rat blood, rat brain homogenate, bovine serum, and human plasma under various conditions."( Stability of heroin, 6-monoacetylmorphine, and morphine in biological samples and validation of an LC-MS assay for delayed analyses of pharmacokinetic samples in rats.
Birnbaum, AK; Harmon, TM; Jones, JM; Keyler, DE; Pentel, PR; Raleigh, MD; Remmel, RP, 2013
)
0.39
"Ethanol and heroin are both depressant drugs on the central nervous system, and combined use is known to be dangerous due to pharmacodynamic interactions, leading to an even higher risk of respiratory depression and death."( Pharmacokinetic interactions between ethanol and heroin: a study on post-mortem cases.
Andersen, JM; Handal, M; Høiseth, G; Mørland, J; Thaulow, CH, 2014
)
0.4
" This pharmacokinetic interaction could further complicate the outcome after combined use of heroin and ethanol, in addition to the already well-known pharmacodynamic interactions."( Pharmacokinetic interactions between ethanol and heroin: a study on post-mortem cases.
Andersen, JM; Handal, M; Høiseth, G; Mørland, J; Thaulow, CH, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this work, we developed an ultra-performance liquid chromatography-time-of-flight mass spectrometry method (UPLC-TOF-MS) with online data acquisition and multiple post-data-mining technologies combined with a multivariate statistical and batch validation analysis workflow to assess the characteristic urine metabolites of heroin abusers."( Identification of characteristic heroin metabolites in urine based on data-mining technology and multivariate statistics analysis combined with a targeted verification approach for distinguishing heroin abusers.
Cui, Y; Guo, D; Li, Q; Liu, G; Liu, Y; Qiao, S; Wang, W; Xu, H; Xu, W; Yang, W; Yu, H; Zhang, W, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of inhaled heroin was estimated to be 53% (95% CI 43."( Population pharmacokinetics of heroin and its major metabolites.
Beijnen, JH; Huitema, AD; Rook, EJ; van den Brink, W; van Ree, JM, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" The dose-response and naloxone antagonism studies suggest that the receptor mechanisms which may subserve opiate convulsions differ from those mediating either analgesia or depressant lethality."( Heroin: analgesia, toxicity and disposition in the mouse.
Inturrisi, CE; Umans, JG, 1982
)
0.26
"Diacetylmorphine (DAM) and 6-acetylmorphine (AM) exhibit virtually identical dose-response and time-action profiles in studies in antinociceptive, excitatory, antidiarrheal and antidiuretic activity after subcutaneous administration to mice."( Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetylmorphine and morphine in mice.
Inturrisi, CE; Umans, JG, 1981
)
0.26
" The statistical distribution of the drug concentrations compared with the self-reported consumption behaviour of the users may possibly lead to a better understanding of the relationship between drug dosage and corresponding concentrations in hair."( Concentrations of delta 9-tetrahydrocannabinol, cocaine and 6-monoacetylmorphine in hair of drug abusers.
Kauert, G; Röhrich, J, 1996
)
0.29
" The sweat patch was applied 10 min before the first dosage and removed approximately 24 h later, minutes before the next dosage."( Sweat testing for heroin and metabolites in a heroin maintenance program.
Brenneisen, R; Bundeli, P; Kintz, P; Mangin, P, 1997
)
0.3
" The same dosing sequence was repeated in week 8 with doubled doses (high-dose week)."( Drug testing with alternative matrices II. Mechanisms of cocaine and codeine deposition in hair.
Cone, EJ; Höld, KM; Joseph, RE; Rollins, DE; Wilkins, DG, 1999
)
0.3
" As previously reported urine concentrations varied greatly between subjects and within subjects with time after dosing but were much more predictable when values were reported as amount of drug per unit of creatinine."( Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin.
Cone, EJ; Darwin, WD; Jenkins, AJ; Paul, BD; Shimomura, ET; Smith, ML; Summers, J, 2001
)
0.31
" There were no differences in the response between heroin and 6MAM, although we observed a shift to the left of the dose-response curve for the maximal response of heroin."( Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo.
Andersen, JM; Boix, F; Mørland, J; Normann, PT; Ripel, A, 2009
)
0.35
" Methadone treatment was switched to SROM with flexible dosing and vice versa according to period and sequence of treatment."( Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone.
Backmund, M; Beck, T; Haasen, C; Reimer, J; Ruckes, C; Schuler, C; Verthein, U; Walcher, S, 2014
)
0.4
" Finally, a screening level risk assessment that combines the measured environmental concentrations (MECs) with dose-response data to estimate Hazard Quotients (HQs) for the compounds studied is also presented."( Drugs of abuse and benzodiazepines in the Madrid Region (Central Spain): seasonal variation in river waters, occurrence in tap water and potential environmental and human risk.
Barceló, D; González-Alonso, S; López de Alda, M; Mastroianni, N; Mendoza, A; Rodríguez-Gil, JL; Valcárcel, Y, 2014
)
0.4
"The purpose of this study was to evaluate the effects of a morphine-conjugate vaccine (M-KLH) on the acquisition, maintenance, and reinstatement of heroin self-administration (HSA) in rats, and on heroin and metabolite distribution during heroin administration that approximated the self-administered dosing rate."( Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats.
LeSage, MG; Pentel, PR; Raleigh, MD, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Heroin metabolism03

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mas-related G-protein coupled receptor member X2Homo sapiens (human)EC50 (µMol)16.50000.14003.73818.9000AID1802708; AID1802709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
sensory perception of painMas-related G-protein coupled receptor member X2Homo sapiens (human)
sleepMas-related G-protein coupled receptor member X2Homo sapiens (human)
positive regulation of cytokinesisMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell degranulationMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell activationMas-related G-protein coupled receptor member X2Homo sapiens (human)
G protein-coupled receptor signaling pathwayMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
G protein-coupled receptor activityMas-related G-protein coupled receptor member X2Homo sapiens (human)
neuropeptide bindingMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell secretagogue receptor activityMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
membraneMas-related G-protein coupled receptor member X2Homo sapiens (human)
plasma membraneMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID456232Activity at human recombinant CES1 expressed in baculovirus-infected Spodoptera frugiperda Sf21 cells assessed as substrate hydrolysis by fluorescence assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations.
AID19240Partition coefficient of Zwitterion (logD)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID18980Log D of compound; LogD at pH 7.41996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID25850Phenolic pKa of compound1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID19243Partition coefficient of anion (logD)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID25846Amine pKa of compound1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID19246Partition coefficient of cation (logD)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID1802709PRESTO-Tango Assay from Article 10.1038/nchembio.2334: \\In silico design of novel probes for the atypical opioid receptor MRGPRX2.\\2017Nature chemical biology, 05, Volume: 13, Issue:5
In silico design of novel probes for the atypical opioid receptor MRGPRX2.
AID1802708Intracellular Calcium Mobilization Assay from Article 10.1038/nchembio.2334: \\In silico design of novel probes for the atypical opioid receptor MRGPRX2.\\2017Nature chemical biology, 05, Volume: 13, Issue:5
In silico design of novel probes for the atypical opioid receptor MRGPRX2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (313)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (8.95)18.7374
1990's77 (24.60)18.2507
2000's71 (22.68)29.6817
2010's118 (37.70)24.3611
2020's19 (6.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (1.96%)5.53%
Reviews9 (2.51%)6.00%
Case Studies21 (5.87%)4.05%
Observational1 (0.28%)0.25%
Other320 (89.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]